IMFINZI (durvalumab) injection
IMFINZI is a brand-name prescription medication that’s used to treat urothelial carcinoma, non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC). Brand Name: IMFINZI (durvalumab) injection, for intravenous use Initial U.S. Approval: 2017.
Home | (durvalumab) injection
Submit a request to access drug used to treat, diagnose or prevent serious or life-threatening conditions.We’ll get back to you within 1 business days!
For Overseas Patient/ Export inquires.
For any urgent inquiries or assistance needed, please reach out to our Support Team. Rest assured, we will respond within 24 hours, from Monday to Saturday, during the hours of 9:00 A.M to 18:00 PM.
IMFINZI (durvalumab) injection
Durvalumab is approved to treat: urothelial carcinoma, non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC). Durvalumab is also being studied in the treatment of other types of cancer.
IMFINZI is a prescription medicine used to treat adults with:
o a type of cancer in the bladder and urinary tract called urothelial carcinoma.
o a type of lung cancer called non-small cell lung cancer (NSCLC).
o a type of lung cancer called small cell lung cancer (SCLC). IMFINZI may be used with the chemotherapy medicines etoposide and carboplatin or cisplatin as your first treatment,
Durvalumab, sold under the brand name Imfinzi, is an FDA-approved immunotherapy for cancer, developed by Medimmune/AstraZeneca. It is a human immunoglobulin G1 kappa (IgG1κ) monoclonal antibody that blocks the interaction of programmed cell death ligand 1 (PD-L1) with the PD-1 (CD279). Durvalumab is an immune checkpoint inhibitor drug.
Drug (Brand / Generic): IMFINZI / durvalumab injection
Current Indications: urothelial carcinoma, non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC)
Marketed by:: AstraZeneca
Approval Date: 2017
Available as (Form & Strength): • Injection: 500 mg/10 mL (50 mg/mL) solution in a single-dose vial.
• Injection: 120 mg/2.4 mL (50 mg/mL) solution in a single-dose vial.
Find Reference Updates
Alleviare Life Sciences
Alleviare Life Sciences Pvt. Ltd. (India) serves as a facilitator for medical and pharmaceutical products, commencing its operations in 2005. Headquartered in Delhi, India, Alleviare operates nationwide, providing a range of comprehensive services to patients, doctors, hospitals, and government healthcare facilities.
Our specialization lies in facilitating access to medicines, leveraging our expertise in sourcing and providing documentation assistance for programs such as Named Patient Program, Managed Access Program, and Early Access Program. We take pride in ensuring smooth and efficient access to medications for those who require them.
Alleviare India is certified pharmaceutical facilitator / supplier / importer based in india. They are also who GDP certified. One of the pharmaceutical products they offer is “IMFINZI (durvalumab) injection”.
Confirmation of the order for IMFINZI (durvalumab) injection will be subject to the submission of a valid doctor’s prescription and, if applicable, an import permit.
We have delivered medicines to following cities in India – Ahmedabad, Aizawal, Aurangabad, Barshi, Bengaluru, Bhopal, Cachar, Chennai, Dibrugarh, Hyderabad, Karungapally, Kohima, Kollam, Kolkata, Mumbai, Meghalaya, Mizoram, Sikkim, Nagpur, New Delhi, Pondichery, Pune, Punjab, Thirunananthapuram, Tripura, Wardha
ALS serves as a facilitator, supplier & exporter in India assisting patients, doctors, and hospitals in importing the prescription medicine brand IMFINZI (durvalumab) injection. The import process requires a valid prescription and an Import License in the Patient’s Name.
For patients from following foreign countries seeking access to IMFINZI (durvalumab) injection, they can inquire and find further information by sending their inquiries to ALS.
We have delivered medicines to following countries – Argentina, Australia, Austria, Azerbaijan, Bahrain, Brazil, Bulgaria, Cambodia, Canada, Chile, Colombia, Costa Rica, Croatia, Cyprus, Denmark, Dominican Republic, Estonia, Finland, France, Georgia, Germany, Ghana, Greece, Guatemala, India, Iraq, Ireland, Israel, Italy, Jamaica, Japan, Jordan, Kenya, Kuwait, Latvia, Lebanon, Libya, Lithuania, Malawi, Mexico, Montenegro, Nepal, Netherlands, New Zealand, Nigeria, Norway, Oman, Pakistan, Paraguay, Peru, Poland, Qatar, Romania, Saudi Arabia, Serbia, Singapore, Slovenia, Spain, Sri Lanka, Sweden, Switzerland, United Arab Emirates, United Kingdom, United States, Venezuela, Zimbabwe.
Kindly reach out to us for IMFINZI (durvalumab) injection price and availability confirmation.
The price of the medicines is the cost set by the manufacturer. In addition, Named Patient support fee, shipping costs and any local tax (if applicable) will apply.